Zai Lab Limited (ZLAB) and Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Contrasting side by side

We are comparing Zai Lab Limited (NASDAQ:ZLAB) and Intra-Cellular Therapies Inc. (NASDAQ:ITCI) on their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zai Lab Limited N/A 0.00 67.46M -2.65 0.00
Intra-Cellular Therapies Inc. N/A 144962.44 144.59M -2.67 0.00

Demonstrates Zai Lab Limited and Intra-Cellular Therapies Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 demonstrates the return on equity, return on assets and net margins of Zai Lab Limited and Intra-Cellular Therapies Inc.

Net Margins Return on Equity Return on Assets
Zai Lab Limited 0.00% 0% 0%
Intra-Cellular Therapies Inc. 0.00% -35.7% -33.7%

Liquidity

Zai Lab Limited’s Current Ratio and Quick Ratio are 17.8 and 17.8 respectively. The Current Ratio and Quick Ratio of its competitor Intra-Cellular Therapies Inc. are 13.2 and 13.2 respectively. Zai Lab Limited therefore has a better chance of paying off short and long-term obligations compared to Intra-Cellular Therapies Inc.

Analyst Ratings

The table delivered features the ratings and recommendations for Zai Lab Limited and Intra-Cellular Therapies Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Zai Lab Limited 0 0 0 0.00
Intra-Cellular Therapies Inc. 0 0 2 3.00

Competitively Intra-Cellular Therapies Inc. has an average target price of $29.5, with potential upside of 120.31%.

Insider & Institutional Ownership

Institutional investors held 66.4% of Zai Lab Limited shares and 79.2% of Intra-Cellular Therapies Inc. shares. Insiders held roughly 35.54% of Zai Lab Limited’s shares. Competitively, insiders own roughly 1.5% of Intra-Cellular Therapies Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Zai Lab Limited 1.01% 8.85% 11.91% -16.51% -22.04% -6.17%
Intra-Cellular Therapies Inc. 6.16% -21.13% -28.78% -29.76% 1.66% 5.94%

For the past year Zai Lab Limited had bearish trend while Intra-Cellular Therapies Inc. had bullish trend.

Summary

Zai Lab Limited beats on 5 of the 8 factors Intra-Cellular Therapies Inc.

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus. The company was founded in 2013 and is headquartered in Shanghai, China.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including ParkinsonÂ’s and AlzheimerÂ’s disease. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.